Trial reportJournal of thrombosis and thrombolysis2013
The Swiss cohort of elderly patients with venous thromboembolism (SWITCO65+): rationale and methodology.
Trial report in Journal of thrombosis and thrombolysis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Trial
- Baseline platelet count and long-term clinical outcomes in patients with acute venous thromboembolism: a prospective cohort study.Annals of hematology · 2024Article
- Risk Assessment Models for Venous Thromboembolism in Medical Inpatients.JAMA network open · 2024Article
- Association between severity of pulmonary embolism and health-related quality of life.Journal of thrombosis and haemostasis : JTH · 2024Article
- Thrombin Generation Is Associated with Venous Thromboembolism Recurrence, but Not with Major Bleeding and Death in the Elderly: A Prospective Multicenter Cohort Study.Journal of clinical medicine · 2023Article
- The value of distinguishing patients with isolated subsegmental pulmonary embolism presenting to two tertiary hospitals in Australia: an observational study.Journal of thrombosis and thrombolysis · 2023Observational
- Incidence and clinical impact of bleeding events in older patients with acute venous thromboembolism.Blood advances · 2023Article
- Thrombophilia and outcomes of venous thromboembolism in older patients.Research and practice in thrombosis and haemostasis · 2023Article
- Risk stratification for hospital-acquired venous thromboembolism in medical patients (RISE): Protocol for a prospective cohort study.PloS one · 2022Article
- Novel Blood Biomarkers for a Diagnostic Workup of Acute Aortic Dissection.Diagnostics (Basel, Switzerland) · 2021Article
- Underuse of medical thromboprophylaxis in mobile elderly inpatients: The SWITCO65+ cohort.Research and practice in thrombosis and haemostasis · 2021Article
- Article
- Elevated HbA1c is not associated with recurrent venous thromboembolism in the elderly, but with all-cause mortality- the SWEETCO 65+ study.Scientific reports · 2020Article
- Oral Intake of EPA:DHA 6:1 by Middle-Aged Rats for One Week Improves Age-Related Endothelial Dysfunction in Both the Femoral Artery and Vein: Role of Cyclooxygenases.International journal of molecular sciences · 2020Article
- Statin therapy and recurrent venous thromboembolism in the elderly: a prospective cohort study.Scientific reports · 2019Observational
- A high Gas6 level in plasma predicts venous thromboembolism recurrence, major bleeding and mortality in the elderly: a prospective multicenter cohort study.Journal of thrombosis and haemostasis : JTH · 2019Article
- Circulating extracellular DNA is an independent predictor of mortality in elderly patients with venous thromboembolism.PloS one · 2018Article
- Article
- Comparison of Cardiac and Non-Cardiac Biomarkers for Risk Stratification in Elderly Patients with Non-Massive Pulmonary Embolism.PloS one · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (VTE) is common and has a high impact on morbidity, mortality, and costs of care. Although most of the patients with VTE are aged ≥65 years, there is little data about the medical outcomes in the elderly with VTE. The Swiss Cohort of Elderly Patients with VTE (SWITCO65+) is a prospective multicenter cohort study of in- and outpatients aged ≥65 years with acute VTE from all five Swiss university and four high-volume non-university hospitals. The goal is to examine which clinical and biological factors and processes of care drive short- and long-term medical outcomes, health-related quality of life, and medical resource utilization in elderly patients with acute VTE. The cohort also includes a large biobank with biological material from each participant. From September 2009 to March 2012, 1,863 elderly patients with VTE were screened and 1003 (53.8%) were enrolled in the cohort. Overall, 51.7% of patients were aged ≥75 years and 52.7% were men. By October 16, 2012, after an average follow-up time of 512 days, 799 (79.7%) patients were still actively participating. SWITCO65+ is a unique opportunity to study short- and long-term outcomes in elderly patients with VTE. The Steering Committee encourages national and international collaborative research projects related to SWITCO65+, including sharing anonymized data and biological samples.
Indexed as
Identifiers
23359097What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.